Company Profile
Nexvet Biopharma public limited company and its subsidiaries (the “Company”) is a clinical-stage biopharmaceutical company focused on transforming the therapeutic market for companion animals by developing and commercializing novel, species-specific biologics. Biologics are therapeutic proteins derived from biological sources. As a class, biologics have transformed human medicine in recent decades and represent many of the top-selling therapies on the market today. The Company’s platform technology, which it refers to as “PETization,” is an algorithmic approach that enables the Company to rapidly create monoclonal antibodies (“mAbs”) a type of biologic, that are designed to be recognized as “self” or “native” by an animal’s immune system, a property referred to as “100% species-specificity.” PETization is designed to build upon the safety and efficacy data from clinically tested human therapies to cre... more >
Recent Newsmore >
DateTitle
31 July 2017Zoetis completes acquisition of Nexvet
... 
28 July 2017Nexvet Biopharma plc ("Nexvet") Rule 17(d) Announcement
DUBLIN, Ireland, July 28, 2017 (GLOBE NEWSWIRE) -- Nexvet Biopharma (Nasdaq:NVET) today announced the following; Recommended Acquisition for Cash by ZOETIS BELGIUM S.A. A WHOLLY-OWNED INDIRECT SUBSIDIARY OF ZOETIS INC. of NEXVET BIOPHARMA PLC to be implemented by means of a scheme of arrangement under Chapter 1 of Part 9 of the Irish Companies Act 2014 Announcement relating to the outcome of the Court Sanction Hearing Nexvet Biopharma plc ("Nexvet" or the "Company") today announce... 
10 July 2017Nexvet Biopharma plc ("Nexvet") Rule 17(c) Announcement
DUBLIN, Ireland, July 10, 2017 (GLOBE NEWSWIRE) -- Nexvet Biopharma (Nasdaq:NVET) today announced the following; Recommended Acquisition for Cash by ZOETIS BELGIUM S.A. A WHOLLY-OWNED INDIRECT SUBSIDIARY OF ZOETIS INC. of NEXVET BIOPHARMA PLC to be implemented by means of a scheme of arrangement under Chapter 1 of Part 9 of the Irish Companies Act 2014 Announcement relating to the results of the Scheme Meeting and Extraordinary General Meeting Nexvet Biopharma plc ("Nexvet" or the ... 
05 July 2017Nexvet Biopharma plc ("Nexvet") Rule 2.10 Announcement
DUBLIN, Ireland, July 05, 2017 (GLOBE NEWSWIRE) -- Nexvet Biopharma (Nasdaq:NVET) today announced the following; In accordance with Rule 2.10 of the Irish Takeover Panel Act 1997, Takeover Rules, 2013 (the "Irish Takeover Rules"), Nexvet confirms that as at close of business on July 3, 2017 its issued share capital comprised 12,144,941 ordinary shares of $0.125 each (the “Ordinary Shares”). The Ordinary Shares are admitted to trading on NASDAQ under the ticker symbol NVET. The International... 
Featured Items
Download Documentation Nexvet Cowen Health Care Conference Corporate Overview
Stock Quotemore >
NVET (ADS)
Exchange :NASDAQ
Price :$6.72
Change :0.00 (0.00%)
Volume :0
Data as of 07/28/17 12:51 p.m. ET
Minimum 20 minute delay
Receive Email AlertsE-mail Alert Icon
Sign up to receive email alerts whenever Nexvet Biopharma plc posts new information to the site. Just enter your email address and click Submit.
 


Data Provided by Thomson Reuters

Nexvet Biopharma

Ireland
Unit 5, Sragh Technology Park
Rahan Road, Tullamore
Co. Offaly, R35 FR98
P: + 353 5793 24522

Australia
Level 8, 31 Queen Street
Melbourne 3000
Victoria
P: +61 (3) 9610 4400

United States
275 Post Street
4th Floor
San Francisco, CA 94108

Email: info@nexvet.com